Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Cash Flows from Operating Activities:
Net Income (loss)	$ (849)	$ 35,090
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	977	990
Loss on extinguishment of debt	0	6,006
(Gain) from change in fair value of hybrid financial instruments	(5,351)	(10,932)
(Gain) from change in fair value of derivative liability - warrants	12,223	(11,615)
(Gain) from change in fair value of derivative liability - Series C and D preferred stock and debentures	(15,715)	(26,949)
Interest expense related to convertible debt	4,378	2,217
Interest paid on convertible debt	(1,000)	(1,000)
Stock-based compensation expense	66	165
Increase in value of life insurance policies	86	(79)
Changes in operating assets and liabilities
Trade and other accounts receivable	(329)	29
Inventories	112	12
Prepaid expenses and other assets	99	128
Accounts payable and accrued liabilities	447	(367)
Deferred revenue and other current liabilities	403	626
Net cash used in operating activities	(4,453)	(5,679)
Cash Flows from Investing Activities:
Acquisition of property and equipment	(2)	(15)
Net cash used in investing activities	(2)	(15)
Cash Flows from Financing Activities:
Proceeds from issuance of Series D preferred stock	0	2,500
Costs attributed to issuance of Series D convertible preferred stock	0	(100)
Borrowing (repayment) of note payable - YA Global	0	(500)
Borrowings under convertible debt instruments, net	4,410	3,665
Net cash provided by financing activities	4,410	5,565
Effect of exchange rate changes on cash	(5)	11
Net increase in cash and cash equivalents	(50)	(118)
Cash and cash equivalents, beginning of period	80	198
Cash and cash equivalents, end of period	30	80
Supplemental cash flow information:
Interest paid during the period	1,001	1,001
Acquisition of patent rights included in accounts payable	0	333
Series C preferred stock converted to common stock	9,874	631
Series D preferred stock converted to common stock	1,951	0
Convertible Debentures converted to common stock	4,307	119
Deemed dividend on Series D preferred stock issued	225	2,500
Shares issued for acquisition of patent rights	$ 350	$ 0